For the abstract please provide an overview paragraph here and then fill in the bulleted sections below. Feel free to modify the bulleted section. Leverage content from a brochure if you have one.
Several antipsychotic therapies are available for the treatment of schizophrenia and primarily control the positive symptoms of the disease. However, given that a sizable portion of schizophrenia patients do not respond adequately to current antipsychotics and that treatment is highly individualized, multiple drug development opportunities exist in this market. With the entry of newer long-acting depot atypical antipsychotics (e.g., Janssen’s Invega Trinza / Trevicta) and oral antipsychotics (e.g., Allergan / Gedeon Richter / Recordati’s Vraylar / Reagila), it is essential to understand how psychiatrists perceive the performance of current therapies and to determine the greatest areas of unmet need in this space. Moreover, with the anticipated availability of new therapies in the near future (e.g., Alkermes’s ALKS-3831), it is important to evaluate the remaining areas of opportunity in this market.
- How do psychiatrists rate current antipsychotics as performing on key treatment drivers and goals for the positive symptoms of schizophrenia?
- Which attributes are key influencers, which have limited impact, and which are hidden opportunities in the positive symptoms of schizophrenia?
- What are the prevailing areas of unmet need and opportunity in the treatment of the positive symptoms of schizophrenia?
- What trade-offs across key drug attributes and price are acceptable to psychiatrists for a hypothetical new drug for the positive symptoms of schizophrenia?
Geographies: United States, France, Germany, United Kingdom
Primary Research: Survey of 60 U.S. and 33 European psychiatrists
Key Drugs Covered: Invega Sustenna / Xeplion, Invega Trinza / Trevicta, paliperidone palmitate six-month depot, Rexulti / Rxulti, Vraylar / Reagila, ALKS-3831, lumateperone, pimavanserin, Abilify Maintena, aripiprazole, olanzapine, risperidone
Key Metrics Included:
- Target Product Profile (TPP) simulator based on conjoint analysis methodology.
- Stated versus derived importance of product attributes on prescribing behavior.
- Assessment of current drug performance against treatment drivers and goals.
- Physician perceptions of unmet needs in the indication and related indications.
- Analysis of remaining drug development opportunities.
Unmet Need supports clinical development decisions by identifying key attributes and assessing areas of unmet need for a specific disease or subpopulation. Based on surveys with U.S. and European physicians, this report provides insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities. Two market scenarios are profiled in detail by DRG experts, and additional customized market scenarios can be evaluated with the corresponding TPP simulator.
- Schizophrenia - Unmet Need - Detailed, Expanded Analysis (Positive Symptoms)
Author(s): Himanshu Jain, M.S. Pharm
Himanshu joined the CNS / ophthalmology team at Decision Resources Group in 2016. He has authored content for psychiatry and ophthalmology (retinal / nonretinal) indications, including schizophrenia, age-related macular degeneration, diabetic retinopathy / diabetic macular edema, dry eye disease, glaucoma, and uveitis.
Himanshu has more than ten years of experience working in market research and consulting firms, and has managed multiple market assessment projects, including bottom-up forecasts, across multiple therapy areas. He holds a M.S. degree in Pharmacology and Toxicology from the National Institute of Pharmaceutical Education and Research in India and an Executive Post-Graduate Diploma in International Business from the Indian Institute of Foreign Trade.